We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Gel Extends Release Half-Life of PEGylated Drugs

By LabMedica International staff writers
Posted on 08 Jul 2015
Print article
Image: Photograph (left) and optical microscopic (right) images of the new hydrogels with polyethylene glycol (PEG) microstructures developed to enable burst-free sustained-release of PEGylated protein drugs such as PEGylated interferon (Photo courtesy of A*STAR’s Institute of Bioengineering and Nanotechnology).
Image: Photograph (left) and optical microscopic (right) images of the new hydrogels with polyethylene glycol (PEG) microstructures developed to enable burst-free sustained-release of PEGylated protein drugs such as PEGylated interferon (Photo courtesy of A*STAR’s Institute of Bioengineering and Nanotechnology).
Researchers have developed a first-of-its-kind hydrogel for more effective long-term drug delivery that would also reduce side-effects and discomfort for patients. Their proof-of-concept study showed effectiveness of the hydrogel with the hepatitis C drug PEGylated-interferon.

The team of researchers, led by Dr. Motoichi Kurisawa, principal research scientist at the Institute of Bioengineering and Nanotechnology (IBN; Singapore) of Singapore’s Agency for Science, Technology and Research (A*STAR), developed a hydrogel that enables burst-free sustained-release of PEGylated protein drugs. “The new gel from IBN prevents premature drug release in the body. This allows for long-term drug delivery and reduces the side effects from frequent drug administration. We hope that our solution can improve the treatment and well-being of patients suffering from chronic diseases such as hepatitis C,” said Prof. Jackie Y. Ying, IBN executive director.

Standard treatment for chronic hepatitis C infections includes weekly injection of PEGylated interferon. The frequent injections increases patient discomfort, is time-consuming, and can cause depression and fatigue. It has not been possible to use hydrogels to deliver drugs with long-term efficacy because controlling the drug release rate is difficult. Most hydrogels have a porous structure that causes the encapsulated drugs to leak prematurely and be eliminated rapidly from the body.

The team found a way to regulate the release rate and duration by creating a gel with 3-D microscopic structures of the polymer polyethylene glycol (PEG). The microstructures function like “reservoirs” for PEGylated drugs because of the presence of PEG on the drug. This property prevents premature leaking. The drugs will also flow in and out of the many reservoirs in the gel before being released into the body. This property helps slow the drug diffusion rate. Duration of drug action can also be controlled by changing the size of the reservoir microstructures.

The study showed that a one-time administration of the hydrogel containing the PEGylated interferon was as effective as 8 injections of the medication alone, and that drug effect can last up to 2 months. The hydrogels will degrade naturally and be eliminated from the body once the drugs are fully released.

“Our hydrogels can significantly extend the half-life of hepatitis C drugs by up to 10 times longer than current treatment,” said Dr. Kurisawa, “This work improves the therapeutic efficiency of the drugs, while reducing the need for frequent injections.” “I believe that our method can pave the way for more effective and safe treatment of hepatitis C. We are also testing the microstructured gel for the treatment of other chronic diseases besides hepatitis C,” added Dr Kurisawa.

The study, by Bae KH et al., was published online ahead of print June 11, 2015, in the journal Biomaterials.

Related Links:

Institute of Bioengineering and Nanotechnology
Singapore Agency for Science, Technology and Research (A*STAR) 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.